News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Jeffrey N. Simmons, CEO of Elanco Animal Health Inc., acquired 117.9362 deferred stock units (DSUs) at $23.97 each on August 21, 2026, as reported in an SEC filing. This transaction increases his direct holdings to 25,130.1237 DSUs. These units, which can be converted to โฆ
Elanco Animal Health Inc's Executive Vice President, Rajeev A. Modi, was granted 61.6158 Deferred Stock Units on August 21, 2026, as part of an award. Each unit represents a share of common stock or its cash equivalent, settling after employment or in a specified โฆ
Elanco Animal Health (ELAN) is a drug manufacturer for specialty and generic animal health products with a market capitalization of $11.97 billion. Analysts project a significant upside potential of approximately 30.22% with an average target price of $31.21, and the company has received 16 โฆ
Lawrence Erik Kurzius, a Director at Elanco Animal Health, recently purchased 40,000 shares of the company's common stock for over $935,000. The shares were bought at a weighted average price of $23.398 each on August 20, 2026. Following this transaction, Kurzius now directly owns โฆ
Lawrence Erik Kurzius, a director at Elanco Animal Health Inc. (NASDAQ:ELAN), purchased 40,000 shares of company stock for approximately $935,920 on August 20, 2026. This transaction increased his direct holdings to 188,647 shares and follows positive news for Elanco, including strong Q2 2026 earnings, โฆ
Elanco Animal Health (NYSE: ELAN) Director Lawrence Erik Kurzius recently purchased 40,000 shares of the company's stock for $936,000, increasing his direct ownership by 26.91%. This insider buying activity follows strong quarterly results where Elanco beat EPS and revenue expectations. Analysts maintain a "Moderate โฆ
Elanco Animal Health Inc (ELAN) director Lawrence Erik Kurzius purchased 40,000 shares of common stock on August 20, 2026, at a weighted average price of $23.398 per share. This open-market transaction increased his direct holdings to 188,647 shares. The purchase is categorized as a โฆ
Danske Bank A S has made a new investment of $14.35 million in Elanco Animal Health Incorporated, acquiring 583,026 shares during the second quarter. This positions Danske Bank A S with approximately 0.12% ownership of the company. The article also details other institutional investments, โฆ
Elanco Animal Health Inc (ELAN) shares fell 3.8% to $23.56, indicating a 41.4% overvaluation according to the GF Valueโข of $16.66. Despite an overall GF Scoreโข of 68/100 and strong momentum, the company faces challenges with financial strength and profitability. Notably, insiders have purchased โฆ
Great Lakes Advisors LLC has purchased 245,707 shares of Elanco Animal Health Incorporated (NYSE:ELAN) valued at approximately $6.05 million. This acquisition is part of broader institutional interest, with 97.48% of the stock owned by institutional investors. Analysts maintain a "Moderate Buy" rating for Elanco, โฆ
Investors who purchased Elanco Animal Health (NYSE: ELAN) common stock between May 9, 2019, and May 6, 2020, may be eligible for a payment from a $15 million SEC fair fund. The fund was established after Elanco paid a civil penalty for failing to โฆ
Elanco Animal Health (NYSE:ELAN) has shown improved operating results and raised its full-year revenue outlook, strengthening its recovery narrative. The company's future valuation hinges on sustained commercial execution, successful product launches, margin improvement, and financial discipline through portfolio changes. While recent momentum is positive, โฆ
Paul Herendeen, Director at Elanco Animal Health (NYSE:ELAN), purchased 10,000 shares of common stock on Aug. 7, 2026, according to an SEC Form 4 filing. Company snapshot Elanco Animal Health is a healthcare company based in Indianapolis. The firm creates, produces, and commercializes solutions โฆ
First National Bank of Omaha recently acquired 160,631 shares of Elanco Animal Health (NYSE:ELAN) valued at approximately $3.97 million during the second quarter. This purchase contributes to institutional investors collectively owning 97.48% of ELAN's outstanding stock. Elanco exceeded quarterly earnings and revenue expectations, and โฆ
Insider Shiv O'neill recently purchased 3,998 shares of Elanco Animal Health (NYSE:ELAN) stock for $94,272.84, increasing direct ownership to 87,832 shares. This transaction follows Elanco's strong Q2 2026 earnings, where EPS and revenue exceeded analyst expectations. The company maintains a "Moderate Buy" consensus rating โฆ
Elanco Animal Health Inc (ELAN) officer Shiv O'Neill, General Counsel and Corporate Secretary, purchased 3,998 shares of common stock on August 18, 2026, at $23.58 per share. This open-market transaction increased O'Neill's direct holdings to 87,832 shares. The purchase was not made under a โฆ
S&CO Inc. recently acquired 111,284 shares of Elanco Animal Health Incorporated (NYSE:ELAN) for approximately $2.74 million, contributing to the 97.48% institutional ownership of the company. Elanco exceeded its Q2 earnings expectations, reporting an adjusted EPS of $0.34 and revenue of $1.37 billion, marking a โฆ
The Seventh Circuit Court of Appeals has ruled against Elanco Animal Health Inc. investors, preventing them from proceeding with claims that the company misrepresented its sales. The court upheld the dismissal of the proposed class action, stating that the investors did not adequately allege โฆ
5 Must-Read Analyst Questions From Elanco's Q2 Earnings Call Elanco's results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, โฆ
J.P. Morgan analyst Chris Schott maintained a Buy rating on Elanco Animal Health (ELAN) with a consensus price target of $31.11, representing a 35.3% upside. Needham analyst Ami Fadia assigned a Buy rating to ACADIA Pharmaceuticals (ACAD) with a price target of $41.00, implying โฆ
Elanco Animal Health president and CEO Jeff Simmons discusses the company's efforts to combat the screwworm outbreak in the United States. The discussion took place on 'The Claman Countdown', highlighting Elanco's expanded response to the health issue.
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jeffrey SimmonsChief Financial Officer - Bob VanHimbergenVice President of Investor Relations and ESG - Tiffany KanagaInvestor Relations - Beth Haney TAKEAWAYS Total โฆ
Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also โฆ
Elanco Animal Health (NYSE:ELAN) Director Paul Herendeen recently purchased 10,000 shares of the company's stock for $236,800, increasing his total ownership to 111,687 shares. This insider buying follows Elanco's strong quarterly earnings report, where the company beat estimates with $0.34 EPS and saw revenue โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States